NYSEAMERICAN:CRMD

CorMedix Stock Forecast, Price & News

$8.01
-0.24 (-2.91 %)
(As of 06/15/2021 03:02 PM ET)
Add
Compare
Today's Range
$7.77
$8.23
50-Day Range
$7.38
$8.65
52-Week Range
$3.86
$18.80
Volume6,680 shs
Average Volume302,687 shs
Market Capitalization$304.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
30 days | 90 days | 365 days | Advanced Chart
Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.


CorMedix logo

About CorMedix

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

492nd out of 2,100 stocks

Pharmaceutical Preparations Industry

239th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Is CorMedix a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CorMedix stock.
View analyst ratings for CorMedix
or view top-rated stocks.

What stocks does MarketBeat like better than CorMedix?

Wall Street analysts have given CorMedix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CorMedix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CorMedix's next earnings date?

CorMedix is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for CorMedix
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) issued its earnings results on Wednesday, May, 12th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. CorMedix had a negative net margin of 9,363.64% and a negative trailing twelve-month return on equity of 53.38%.
View CorMedix's earnings history
.

How has CorMedix's stock been impacted by COVID-19 (Coronavirus)?

CorMedix's stock was trading at $5.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRMD shares have increased by 59.8% and is now trading at $8.02.
View which stocks have been most impacted by COVID-19
.

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

5 analysts have issued 12-month target prices for CorMedix's stock. Their forecasts range from $10.00 to $29.00. On average, they anticipate CorMedix's share price to reach $18.90 in the next year. This suggests a possible upside of 135.7% from the stock's current price.
View analysts' price targets for CorMedix
or view top-rated stocks among Wall Street analysts.

Who are CorMedix's key executives?

CorMedix's management team includes the following people:
  • Mohammed Khoso Baluch, Chief Executive Officer & Director
  • Mathew David, Chief Financial Officer & Executive Vice President
  • Antony E. Pfaffle, Secretary & Chief Scientific Officer
  • John L. Armstrong, EVP-Technical Operations & Head-Human Resources
  • Elizabeth Masson-Hurlburt, Executive Vice President & Head-Clinical Operation

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.93%), Elliott Investment Management L.P. (4.08%), Credit Suisse AG (1.98%), Geode Capital Management LLC (1.40%), Northern Trust Corp (0.88%) and Morgan Stanley (0.74%). Company insiders that own CorMedix stock include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz.
View institutional ownership trends for CorMedix
.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Elliott Investment Management L.P., JPMorgan Chase & Co., Northern Trust Corp, Nuveen Asset Management LLC, Royal Bank of Canada, Bank of New York Mellon Corp, HighTower Advisors LLC, and Rhumbline Advisers.
View insider buying and selling activity for CorMedix
or view top insider-selling stocks.

Which institutional investors are buying CorMedix stock?

CRMD stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, BlackRock Inc., Morgan Stanley, Spinnaker Capital LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., Ameriprise Financial Inc., and Squarepoint Ops LLC. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix
or or view top insider-buying stocks.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $8.02.

How much money does CorMedix make?

CorMedix has a market capitalization of $305.16 million and generates $240,000.00 in revenue each year. The biotechnology company earns $-22,030,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does CorMedix have?

CorMedix employs 30 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

Where are CorMedix's headquarters?

CorMedix is headquartered at 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at (908) 517-9500.


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.